Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trialYi‐Long Wu, Tony Mok, Seiji Niho et al.|The Lancet Oncology|2017Cited by 1.2k
Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long‐term survival follow‐up from the randomized, phase 3 INO‐VATE studyHagop M. Kantarjian, Anjali S. Advani, Wendy Stock et al.|Cancer|2019Cited by 327